ATE370130T1 - Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten - Google Patents
Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthaltenInfo
- Publication number
- ATE370130T1 ATE370130T1 AT01994985T AT01994985T ATE370130T1 AT E370130 T1 ATE370130 T1 AT E370130T1 AT 01994985 T AT01994985 T AT 01994985T AT 01994985 T AT01994985 T AT 01994985T AT E370130 T1 ATE370130 T1 AT E370130T1
- Authority
- AT
- Austria
- Prior art keywords
- agent
- compounds
- compound
- formula
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 abstract 1
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 235000020830 overeating Nutrition 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000392723 | 2000-12-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE370130T1 true ATE370130T1 (de) | 2007-09-15 |
Family
ID=18858667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01994985T ATE370130T1 (de) | 2000-12-25 | 2001-12-21 | Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7220864B2 (de) |
| EP (2) | EP1354879B1 (de) |
| JP (1) | JP3491635B2 (de) |
| KR (2) | KR100718906B1 (de) |
| CN (1) | CN100357280C (de) |
| AT (1) | ATE370130T1 (de) |
| BR (1) | BR0116526A (de) |
| CA (1) | CA2432211C (de) |
| CZ (1) | CZ20031772A3 (de) |
| DE (1) | DE60130031T2 (de) |
| DK (1) | DK1354879T3 (de) |
| ES (1) | ES2291378T3 (de) |
| HU (1) | HUP0303636A3 (de) |
| IL (2) | IL156505A0 (de) |
| MX (1) | MXPA03005763A (de) |
| NO (1) | NO327132B1 (de) |
| NZ (1) | NZ526687A (de) |
| PL (1) | PL207798B1 (de) |
| PT (1) | PT1354879E (de) |
| RU (1) | RU2268262C2 (de) |
| TW (1) | TWI235748B (de) |
| WO (1) | WO2002051820A1 (de) |
| ZA (1) | ZA200304913B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| WO2004011446A1 (en) * | 2002-07-26 | 2004-02-05 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
| JP2005104951A (ja) * | 2003-01-17 | 2005-04-21 | Kirin Brewery Co Ltd | 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品 |
| DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10308354A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10308355A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE10308351A1 (de) * | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| JPWO2005103017A1 (ja) * | 2004-04-20 | 2008-03-13 | 小野薬品工業株式会社 | 難溶性薬物の比表面積増大方法 |
| CA2626443A1 (en) * | 2005-11-07 | 2007-05-18 | Irm Llc | Oxazole and thiazole ppar modulators |
| WO2010047674A1 (en) | 2008-10-20 | 2010-04-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Low molecular weight thyroid stimulating hormone receptor (tshr) agonists |
| JP5965387B2 (ja) | 2010-04-08 | 2016-08-03 | アメリカ合衆国 | Ｔｓｈ受容体用のインバースアゴニストおよびニュートラルアンタゴニスト |
| US20130158063A1 (en) * | 2010-08-24 | 2013-06-20 | Georgetown University | Compounds, Compositions and Methods Related to PPAR Antagonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4317320A1 (de) * | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| WO1999011255A1 (en) * | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
-
2001
- 2001-12-21 RU RU2003118718/04A patent/RU2268262C2/ru not_active IP Right Cessation
- 2001-12-21 IL IL15650501A patent/IL156505A0/xx unknown
- 2001-12-21 KR KR1020067012331A patent/KR100718906B1/ko not_active Expired - Fee Related
- 2001-12-21 MX MXPA03005763A patent/MXPA03005763A/es active IP Right Grant
- 2001-12-21 WO PCT/JP2001/011255 patent/WO2002051820A1/ja not_active Ceased
- 2001-12-21 DK DK01994985T patent/DK1354879T3/da active
- 2001-12-21 ES ES01994985T patent/ES2291378T3/es not_active Expired - Lifetime
- 2001-12-21 US US10/451,679 patent/US7220864B2/en not_active Expired - Fee Related
- 2001-12-21 KR KR1020037008566A patent/KR100635315B1/ko not_active Expired - Fee Related
- 2001-12-21 DE DE60130031T patent/DE60130031T2/de not_active Expired - Lifetime
- 2001-12-21 CA CA2432211A patent/CA2432211C/en not_active Expired - Fee Related
- 2001-12-21 HU HU0303636A patent/HUP0303636A3/hu unknown
- 2001-12-21 NZ NZ526687A patent/NZ526687A/en not_active IP Right Cessation
- 2001-12-21 PL PL363583A patent/PL207798B1/pl not_active IP Right Cessation
- 2001-12-21 EP EP01994985A patent/EP1354879B1/de not_active Expired - Lifetime
- 2001-12-21 AT AT01994985T patent/ATE370130T1/de active
- 2001-12-21 PT PT01994985T patent/PT1354879E/pt unknown
- 2001-12-21 CN CNB018226787A patent/CN100357280C/zh not_active Expired - Fee Related
- 2001-12-21 CZ CZ20031772A patent/CZ20031772A3/cs unknown
- 2001-12-21 JP JP2002552915A patent/JP3491635B2/ja not_active Expired - Fee Related
- 2001-12-21 BR BR0116526-7A patent/BR0116526A/pt not_active IP Right Cessation
- 2001-12-21 EP EP06119088A patent/EP1726586A1/de not_active Withdrawn
- 2001-12-24 TW TW090132011A patent/TWI235748B/zh not_active IP Right Cessation
-
2003
- 2003-06-18 IL IL156505A patent/IL156505A/en not_active IP Right Cessation
- 2003-06-23 NO NO20032895A patent/NO327132B1/no not_active IP Right Cessation
- 2003-06-24 ZA ZA200304913A patent/ZA200304913B/en unknown
-
2006
- 2006-08-17 US US11/505,359 patent/US20060287304A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE451346T1 (de) | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten | |
| ATE370130T1 (de) | Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten | |
| WO2001096311A3 (en) | Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases | |
| EP1122255A4 (de) | Carbonsäurederivate und medikamente die diese als aktiven inhaltsstoff enthalten | |
| BR0016064A (pt) | Compostos heterocìclicos e seus sais e uso medicinal dos mesmos | |
| TNSN04164A1 (fr) | Inhibiteurs de acc. | |
| CA2476800A1 (en) | Crystals of glucopyranosyloxybenzyl benzene derivative | |
| RU2007101492A (ru) | Способ и композиция для лечения ожирения, инсулинзависимых заболеваний и гиперхолестеринемии | |
| CH635096A5 (fr) | Chlorhydrate dihydrate de 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine et medicament le contenant. | |
| EP1108713A4 (de) | Carbonsäurederivate und sie als aktiven bestandteil enthaltende medikamente | |
| JPH01299289A (ja) | 血糖降下剤としてのチアゾリジンジオン誘導体 | |
| WO2009087285A4 (fr) | 5,6-diaryles pyridines substitues en position 2 et 3, leur preparation et leur application en therapeutique | |
| CA2344144A1 (en) | Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | |
| BR9408506A (pt) | Compostos neuroprotetores | |
| ATE15181T1 (de) | (z)-1-aryl-2-aminomethyl-cyclopropan-carboxylat , ihre herstellung und ihre verwendung als arzneimittel fuer die behandlung von verschiedenen schmerzen. | |
| BRPI0408325A (pt) | compostos derivados de imino éter e medicamentos contendo os compostos como o ingrediente ativo | |
| WO2003042194A1 (en) | Carboxylic acid derivative compounds and drugs containing the same as the active ingredient | |
| CA2365085A1 (en) | Therapeutic agents for diabetes | |
| DE69630465D1 (de) | Vorsorge-/heilmittel fur die komplikationen von diabetes | |
| JP2009539877A5 (de) | ||
| Gunalan et al. | Insights of Novel Anti-Inflammatory Drugs Targeting Phosphodiesterase and Their Characterization: An In-Silico and In-Vitro Approach | |
| JPH03193730A (ja) | 治療剤 | |
| KR960704870A (ko) | 숙시남산 화합물, 그의 제조방법 및 그의 용도 (Succinamic Acid Compound, Production Method Thereof And Use Thereof) | |
| KR870008874A (ko) | 4-(2-피리미디닐)-1-피페라지닐 헤테로사이클릭 카보닐유도체 및 그의 제조방법 | |
| FR2822069B1 (fr) | Composition pharmaceutique comprenant un compose stimulant la secretion d'insuline et un derive de thiazolidinedione et son utilisation pour la preparation de medicamments destines a traiter le diabete |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1354879 Country of ref document: EP |